Patients with Churg-Strauss Syndrome (CSS) may benefit from an anti-IL5 monoclonal antibody. This is the result of a study (Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis) published May 18, 2017 in New England Journal of Medicine.
Churg-Strauss Syndrome (CSS), also known as Eosinophilic granulomatosis with polyangiitis (EGPA), is an extremely rare autoimmune condition marked by blood vessel inflammation. It can impair multiple organ systems, such as the lungs, skin, nerves and stomach. The disease generally affects individuals with a history of asthma or allergies. Asthma, eosinophils, fevers, shortness of breath, cough, wheezing, runny nose, sinusitis, and rashes are common symptoms. Left untreated, the disease can be life-threatening.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts. It is used to treat severe eosinophilic asthma, and works by blocking interleukin-5 (IL-5), a protein that functions as a key mediator in eosinophil activation. This protein is known to correlate with several allergic diseases, such as allergic rhinitis and asthma. There is a hyperthesis that anti-IL5 antibodies may not only treat asthma but other diseases. (PODXL Monoclonal Antibody can be offered by CusAb.)
The aim of this study is to test the effect of mepolizumab in CSS. A total of 136 people with CSS participated in the study, and were randomly assigned to receive mepolizumab or a lacebo. Results showed that patients receiving mepolizumab showed accrued weeks of remission, and more patients receiving mepolizumab showed remission. These findings demonstrated the theapeutic effects of the antibody mepolizumab in CSS.
留言列表
